SAGETIS BIOTECH GRANTS EXCLUSIVE LICENSE OF ITS VIROSHIELD TECHNOLOGY TO ARATINGA.BIO TNP FOR RETROV
March 29th, 2019 — Sagetis Biotech, S.L., today announced that it granted an exclusive license to research, develop, use, manufacture, and commercialize its polymeric coating technology (Viroshield) to aratinga.bio TNP. The terms of that license agreement (financial terms not disclosed), gives aratinga.bio TNP worldwide rights to further develop the encapsulation technology for any retroviral-based applications and any plasmid-based applications in any therapeutic area.
The relationship between Sagetis Biotech and aratinga.bio TNP builds upon earlier work conducted by aratinga.bio TNP using polymeric coating technology provided by Sagetis under the terms of a Collaboration Research and Option Agreement established in 2017. Sagetis Biotech will keep providing aratinga.bio TNP its support and know-how in polymer related matters.
Mr. Eduard Diviu, Sagetis’ CEO and co-founder, said: “We are very pleased to announce this licensing agreement with aratinga.bio TNP. This transaction reflects Sagetis strategy to work with selected third parties that have the potential to apply our proprietary technologies in their own developments and treat serious human diseases".
About Sagetis Biotech
Sagetis Biotech is devoted to developing an innovative polymeric technology (Viroshield) to overcome a fundamental engineering challenge in gene therapy: the development of safe and effective delivery vectors. This coating technology is able to modify the behavior of oncolytic viruses, improving their therapeutic effect by different means. The coated oncolytic adenoviruses are protected against pre-existing neutralizing antibodies, by masking their surface antigenic epitopes, while preserving their transduction capability. This technology can be adapted to coat both enveloped and non-enveloped viruses.
Privately funded and based in Barcelona, Sagetis Biotech is also developing SAG-101: a polymer-coated adenovirus for the treatment of pancreatic ductal adenocarcinoma.
Sagetis Biotech has in-licensed in 2013 and 2018 several patent applications from Institut Químic de Sarrià (IQS) and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) that are integrated in the Viroshield technology along with patents of its property.
For more information, please visit www.sagetis-biotech.com
About aratinga.bio TNP
Aratinga.bio TNP is a privately-held, preclinical stage biotechnology company focused on the development of novel immunotherapies including in vivo solutions to reprogram and direct immune cells to recognize and destroy tumors.
To address unmet medical needs, aratinga.bio TNP is developing its proprietary platform effective against both hematological cancers and solid tumors regardless of the type of previous treatments patients have experienced.
For more information, please visit http://www.aratinga.bio